查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1995432

植入炎市場：2026-2032年全球市場預測（依產品類型、治療方法、植入材料、嚴重程度、最終用戶和通路分類）

Peri-implantitis Market by Product Type, Treatment Modality, Implant Material, Severity, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，植入周圍炎市場價值將達到 12.2 億美元，到 2026 年將成長到 13 億美元，到 2032 年將達到 19 億美元，複合年成長率為 6.50%。

主要市場統計數據
基準年 2025 12.2億美元
預計年份：2026年 13億美元
預測年份 2032 19億美元
複合年成長率 (%) 6.50%

針對植入周圍炎，我們提出了一個綜合框架，其中臨床、材料科學和醫療保健系統的挑戰相互交織，需要跨學科的解決方案。

隨著植入長期存活率與患者預期相符，植入炎已成為臨床醫生、醫療設備製造商和醫療保健系統的焦點。本文將植體周圍植入視為一個多方面的挑戰，它不僅是一種臨床併發症，更涵蓋生物材料、臨床通訊協定、監管以及以患者為中心的治療結果。植入的日益普及、對長期美觀和功能永續性的日益重視以及監管力度的加大，都促使人們需要能夠兼顧預防和有效干預的綜合解決方案。

生物材料、診斷技術和跨學科通訊協定的進步如何重塑植體周圍植入治療的臨床路徑和產品開發。

植體周圍植入的治療正經歷著變革性的轉變，這得益於生物材料、微創技術、數位化診斷以及更嚴謹的實證醫學方法等方面的進步，這些方法強調長期的組織穩定性。移植材料成分和膜吸收特性的創新使臨床醫生能夠更精準地根據患者的生物學特徵制定再生策略。同時，雷射輔助療法和改進的輔助器械拓展了非手術治療的選擇範圍，可以延緩或減少侵入性干預的必要性。這些變化伴隨著通訊協定的廣泛轉變，即在促進骨再生的同時，優先考慮軟組織結構的保護。

關稅相關的供應鏈中斷和採購重組對臨床連續性、籌資策略和商業性韌性的影響。

政策變化可能導致關稅調整，這進一步提升了相關人員對跨境供應鏈韌性和籌資策略的關注。對牙科材料、植入輔助器具或進口手術器械徵收關稅可能會增加總體成本，促使供應商多元化，並加速本地化生產和近岸外包。實際上，採購團隊和製造商正在評估採購地點以降低風險，優先考慮多通路採購，並審查合約條款以確保盈利能力並維持對臨床醫生的產品供應。

將產品設計、臨床通訊協定和分銷策略聯繫起來，從而深入了解產品採用和臨床影響最密切相關的細分市場層面的洞察。

細分市場分析提供了一個細緻的觀點，清楚地展現了植入炎治療全過程中臨床需求與商業性機會的交會點。按產品類型分類，市場涵蓋輔助器械、雷射治療、藥物治療和外科手術治療。在外科手術治療中，臨床和監管路徑會因移植材料和膜的選擇而顯著不同。移植材料分為同種異體移植、自體移植、合成移植和異質骨移植，膜則根據其不可吸收和可吸收的性能特徵進行區分。這種細緻的分析表明，外科創新主要集中在將特定移植材料與可預測分解和空間保持的膜相結合的解決方案上。

區域在法律規範、臨床實施模式和供應鏈結構方面的差異，影響植入炎的治療和商業化路徑。

了解區域趨勢對於理解臨床實踐、法規結構和供應鏈結構如何影響植入炎的治療至關重要。在美洲，手術量、綜合牙科服務機構以及對實證報銷機制的高度重視正在影響先進再生材料和輔助器械的採用曲線。該地區私立和保險主導的醫療模式相結合，促使人們展示價值論證和長期治療結果數據，以支持高價值的臨床干預措施。

競爭格局的特點是基於證據的產品差異化、策略夥伴關係以及影響臨床引入和規模化的分銷策略。

植入炎治療領域的競爭動態由產品創新、臨床證據的累積、策略夥伴關係以及服務導向經營模式共同決定。主要企業透過專有的植體配方、具有可預測吸收特性的薄膜技術以及整合到現有臨床工作流程中的輔助設備來脫穎而出。成功越來越取決於在真實臨床環境中證明治療效果可重複性的能力、透過高品質的培訓和病例教學來支持臨床醫生的能力，以及維持強力的上市後監測以持續改進產品的能力。

以證據產生、供應彈性和客製化商業模式為重點的可操作策略重點，旨在加速臨床應用並建立競爭優勢。

產業領導企業應優先考慮將臨床證據的累積、供應鏈韌性和精準的商業策略相結合，以加速永續成長。投資於前瞻性臨床試驗和可操作的註冊登記，能夠增強價值提案並促進與支付方的談判；同時，強調通訊協定標準化和結果測量的臨床醫生教育項目，則有助於推動臨床實踐中的應用。從價值鏈的角度來看，製造地的多元化和緊急庫存計劃的製定，可以減輕國際貿易和關稅變化帶來的成本波動的影響。

為了支持策略性結論，我們採用了嚴謹的多面向研究途徑，整合了臨床文獻綜述、專家訪談和交叉細分分析。

本分析的調查方法系統地檢視了同行評審的臨床文獻、監管申報文件、產品技術文檔，並採訪了臨床醫生、採購經理和行業高管，從而構建了技術趨勢、臨床通訊協定和商業性發展的綜合視角。資料收集著重於臨床結果、醫療設備標籤檢視和監管摘要等一級資訊來源，並輔以定性訪談，以了解最終用戶的實踐模式和採購考量。

整合臨床需求、創新路徑和營運要求，制定推動植入炎治療的策略議程。

植體植入炎不僅為整個牙科生態系統中的相關人員帶來了臨床挑戰，也帶來了策略機會。生物材料、診斷準確性和微創治療方法的進步正在拓展臨床醫生可用的治療手段，而分銷和供應鏈趨勢也在政策和商業性壓力下不斷演變。隨著治療路徑向循證保守策略轉變，能夠將產品創新與可靠的療效數據和穩健的經營模式相結合的製造商和供應商將獲得無可比擬的價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 植體植入炎市場：依產品類型分類

  • 輔助器具
  • 雷射治療
  • 藥物治療
  • 手術治療
    • 嫁接材料的種類
      • 同種異體移植
      • 自體移植
      • 合成
      • 異質骨移植
    • 膜的類型
      • 不吸收
      • 吸收性

第9章 依治療方法分類的植體周圍植入市場

  • 非手術
    • 局部抗菌治療
    • 機械清創
  • 外科
    • 再生療法
    • 切除術

第10章 以植入材料分類的植體周圍植入市場

  • 鈦
  • 氧化鋯

第11章 以嚴重程度分類的植體周圍植入市場

  • 溫和的
  • 緩和
  • 嚴重

第12章 植體植入炎市場：依最終用戶分類

  • 門診手術中心
  • 牙醫診所
  • 醫院

第13章 植體植入炎市場：依通路分類

  • 直銷
  • 銷售代理
  • 線上管道

第14章植入周圍炎市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 植體植入炎市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章植入周圍炎市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國植體植入炎市場

第18章：中國植體植入炎市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • BioHorizons IPH, Inc.
  • CAMLOG Biotechnologies GmbH
  • DENTSPLY SIRONA Inc.
  • Geistlich Pharma AG
  • Institut Straumann AG
  • MIS Implants Technologies Ltd.
  • Nobel Biocare Services AG
  • Osstem Implant Co., Ltd.
  • Osteogenics Biomedical, Inc.
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-4103B31E019B

The Peri-implantitis Market was valued at USD 1.22 billion in 2025 and is projected to grow to USD 1.30 billion in 2026, with a CAGR of 6.50%, reaching USD 1.90 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.22 billion
Estimated Year [2026] USD 1.30 billion
Forecast Year [2032] USD 1.90 billion
CAGR (%) 6.50%

An integrative framing of peri-implantitis as a converging clinical, material science, and health systems challenge demanding multidisciplinary solutions

Peri-implantitis has emerged as a focal point for clinicians, device manufacturers, and health systems as long-term implant survival and patient expectations converge. This introduction frames peri-implantitis not merely as a clinical complication but as a multifaceted challenge that spans biomaterials, clinical protocols, regulatory scrutiny, and patient-centered outcomes. Rising implant utilization, greater emphasis on esthetic and functional longevity, and heightened regulatory attention have collectively intensified the need for integrated solutions that address both prevention and effective intervention.

Clinicians are navigating an expanding therapeutic toolkit that ranges from conservative, non-surgical regimens to complex regenerative surgeries, and manufacturers are responding with adjunctive devices, novel membranes, graft materials, and pharmacologic adjuncts. At the same time, payers and health systems are scrutinizing procedural value and long-term cost implications, driving demand for evidence that links specific interventions to durable clinical benefits. This introduction sets the stage for deeper analysis by outlining the clinical imperatives, stakeholder incentives, and innovation drivers that underpin current industry activity and near-term strategic priorities.

How advances in biomaterials, diagnostics, and interdisciplinary protocols are reshaping clinical pathways and product development across peri-implantitis care

Transformative shifts in peri-implantitis care are being driven by converging advances in biomaterials, minimally invasive techniques, digital diagnostics, and a more rigorous evidence base that emphasizes long-term tissue stability. Innovations in graft composition and membrane resorption profiles are enabling clinicians to tailor regenerative strategies more precisely to patient biology, while laser-assisted modalities and improved adjunctive devices are expanding non-surgical options that can delay or reduce the need for invasive intervention. These shifts are accompanying a broader move toward protocols that prioritize preservation of soft tissue architecture alongside osseous regeneration.

Simultaneously, diagnostic sophistication is improving, with more accurate chairside assessments of soft tissue inflammation, peri-implant probing profiles, and imaging modalities that support earlier, more targeted treatment. The growth of interdisciplinary care pathways-integrating periodontists, restorative dentists, and surgical specialists-has elevated the standard for coordinated management and created opportunities for integrated product-service offerings. Regulatory emphasis on clinical evidence and post-market surveillance is also prompting manufacturers to invest in robust outcomes research, which in turn is reshaping product development priorities toward demonstrable long-term performance and safety.

Implications of tariff-driven supply chain disruption and procurement realignment for clinical continuity, sourcing strategies, and commercial resilience

The prospect of tariff changes originating from policy shifts has sharpened stakeholder attention to cross-border supply chain resilience and procurement strategies. Tariffs applied to dental materials, implant adjuncts, or imported surgical instruments can increase landed costs, compel supplier diversification, and accelerate local manufacturing or nearshoring initiatives. In practice, procurement teams and manufacturers are evaluating sourcing footprints to mitigate exposure, prioritizing multi-sourcing, and re-examining contract terms to preserve margin and maintain product availability for clinicians.

Beyond unit cost implications, tariffs influence inventory strategies and working capital management. Health systems and larger dental groups may respond by increasing buffer stocks of critical consumables, renegotiating distribution agreements, or shifting to contract manufacturing arrangements that localize production of grafts, membranes, or disposable adjunctive devices. The dynamic also elevates the strategic value of distributor relationships and online channels as firms seek resilient and flexible pathways to market. Ultimately, tariff-driven pressures reinforce the importance of supply chain transparency, cost-to-serve analyses, and scenario planning to sustain clinical continuity and preserve competitive positioning.

Segment-level insights that connect product design, clinical protocols, and distribution strategies to where adoption and clinical impact are most likely to converge

Segmentation analysis provides a nuanced lens that clarifies where clinical demand and commercial opportunity intersect across the peri-implantitis care continuum. When examined through product type, the market encompasses adjunctive devices, laser treatment, pharmacological treatment, and surgical treatment; within surgical approaches, graft types and membrane options present distinct clinical and regulatory pathways, with graft materials categorized as allograft, autograft, synthetic, and xenograft, and membranes differentiated by non-resorbable versus resorbable performance characteristics. This granularity reveals that surgical innovation is often concentrated in combination solutions that link specific graft materials to membranes engineered for predictable degradation and space maintenance.

Viewing the landscape by treatment modality highlights a split between non-surgical strategies-such as local antibiotic therapy and mechanical debridement-and surgical protocols that include regenerative procedures and resective measures. The balance between these modalities is shaped by disease severity and clinician preference, with non-surgical options playing a larger role in early-stage management and regenerative approaches becoming central when tissue preservation and restoration are required. End-user segmentation captures divergent procurement and clinical workflows across ambulatory surgery centers, dental clinics, and hospitals, each presenting distinct purchasing cycles, reimbursement interactions, and procedural throughput considerations. Distribution channels-whether direct sales, distributor networks, or online channels-modulate commercial access and support models, while implant material choice between titanium and zirconia and clinical severity strata of mild, moderate, and severe cases further refine product positioning and clinical protocol selection. Integrating these segmentation dimensions enables a strategic view of where targeted clinical evidence, education, and go-to-market alignment can most effectively accelerate adoption.

Regional contrasts in regulatory frameworks, clinical adoption patterns, and supply chain structures that shape peri-implantitis care and commercialization pathways

Regional dynamics are critical to understanding how clinical practices, regulatory frameworks, and supply chain architectures shape peri-implantitis management. In the Americas, procedural volumes, consolidated dental service organizations, and a strong emphasis on evidence-based reimbursement mechanisms influence adoption curves for advanced regenerative materials and adjunctive devices. This region's mix of private-pay and insurance-driven care incentivizes value demonstrations and long-term outcome data to support premium clinical interventions.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory regimes and public health structures vary significantly, resulting in diverse adoption timelines for new materials and techniques. In some markets, centralized procurement and hospital-led programs favor standardized product portfolios, whereas private specialty clinics drive early adoption of innovative lasers and biologics. The Asia-Pacific region is characterized by rapid clinical modernization, growing domestic manufacturing capabilities, and increasing investment in dental education and specialist training, which together accelerate both procedural uptake and local innovation in implant materials and adjunctive technologies. These regional contrasts underscore the importance of tailored regulatory strategies, localized clinical evidence generation, and distribution models that reflect payer structures and provider ecosystems.

Competitive landscape characterized by evidence-driven product differentiation, strategic partnerships, and distribution choices that influence clinical adoption and scale

Competitive dynamics in peri-implantitis care are defined by a combination of product innovation, clinical evidence generation, strategic partnerships, and service-oriented commercial models. Leading companies are differentiating through proprietary graft formulations, membrane technologies with predictable resorption profiles, and adjunctive devices that integrate into established clinical workflows. Success is increasingly tied to the ability to demonstrate reproducible outcomes in real-world settings, to support clinicians with high-quality training and case-based education, and to maintain robust post-market surveillance that informs iterative product improvements.

Strategic alliances between device manufacturers, research institutions, and specialty clinics are accelerating clinical validation and building trusted clinical advocates. Meanwhile, firms that can efficiently navigate regulatory pathways and scale manufacturing for complex biological materials gain an operational edge. Distribution strategies vary, with some companies favoring direct engagement for high-touch accounts while others leverage distributor networks and online channels to broaden reach. Companies that align product portfolios with reimbursement pathways and that invest in digital tools to facilitate clinician engagement and patient communication are better positioned to convert clinical promise into sustained utilization.

Actionable strategic priorities focused on evidence generation, supply resilience, and tailored commercial models to accelerate clinical adoption and competitive differentiation

Industry leaders should prioritize a combination of clinical evidence generation, supply chain resilience, and targeted commercial strategies to accelerate sustainable growth. Investing in prospective clinical studies and pragmatic registries will strengthen value propositions and support payer discussions, while clinician education programs that emphasize protocol standardization and outcomes measurement will enhance real-world adoption. From a supply chain perspective, diversifying manufacturing footprints and establishing contingency inventory plans can reduce exposure to international trade shifts and tariff-driven cost variability.

Commercially, aligning distribution strategies with the end-user profile is essential: complex biologics and high-touch regenerative systems benefit from direct sales and dedicated clinician support, whereas adjunctive devices and consumables can leverage distributors and online channels for scale. Strategic collaborations with academic centers and specialty networks can amplify clinical credibility, and embedding digital tools that facilitate case documentation and patient follow-up will differentiate offerings in a crowded market. Finally, designing product portfolios that accommodate both titanium and zirconia implant ecosystems and that address the full spectrum of disease severity-from mild to severe-will broaden clinical applicability and reduce barriers to adoption.

A rigorous multi-source research approach blending clinical literature review, expert interviews, and cross-segmentation analysis to underpin strategic conclusions

The research methodology underpinning this analysis combined a systematic review of peer-reviewed clinical literature, regulatory filings, technical product documentation, and interviews with practicing clinicians, procurement leaders, and industry executives to create an integrated view of technological trends, clinical protocols, and commercial dynamics. Data collection emphasized primary-source clinical outcomes, device labeling, and regulatory summaries, supplemented by qualitative interviews that contextualized practice patterns and procurement considerations across end users.

Analytical methods included cross-segmentation mapping to identify where product innovation intersects with clinical need, scenario-based supply chain stress-testing to examine tariff and sourcing implications, and comparative evaluation of distribution models relative to end-user purchasing behavior. Throughout, care was taken to triangulate findings across multiple sources and expert perspectives to ensure robustness and to highlight prevailing uncertainties that warrant further investigation or localized validation.

Synthesis of clinical imperatives, innovation pathways, and operational imperatives that together define the strategic agenda for advancing peri-implantitis care

Peri-implantitis presents both a clinical challenge and a strategic opportunity for stakeholders across the dental ecosystem. Advances in biomaterials, diagnostic precision, and minimally invasive modalities are expanding the toolkit available to clinicians, while distribution and supply chain dynamics are evolving in response to policy and commercial pressures. As care pathways shift toward evidence-driven, preservation-focused strategies, manufacturers and providers that align product innovation with robust outcome data and resilient commercial models will capture disproportionate value.

Sustained progress will depend on interdisciplinary collaboration, investment in real-world evidence generation, and pragmatic supply chain planning that mitigates external risks such as tariff fluctuations. Clinicians seeking to improve patient outcomes should emphasize early detection and protocolized intervention, while payers and health systems should incentivize treatments that demonstrate durable clinical benefit. The conclusion underscores a shared imperative: integrating clinical excellence, operational resilience, and strategic commercialization to transform peri-implantitis care from episodic treatment toward predictable, long-term implant preservation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Peri-implantitis Market, by Product Type

  • 8.1. Adjunctive Devices
  • 8.2. Laser Treatment
  • 8.3. Pharmacological Treatment
  • 8.4. Surgical Treatment
    • 8.4.1. Graft Type
      • 8.4.1.1. Allograft
      • 8.4.1.2. Autograft
      • 8.4.1.3. Synthetic
      • 8.4.1.4. Xenograft
    • 8.4.2. Membrane Type
      • 8.4.2.1. Non-Resorbable
      • 8.4.2.2. Resorbable

9. Peri-implantitis Market, by Treatment Modality

  • 9.1. Non Surgical
    • 9.1.1. Local Antibiotic Therapy
    • 9.1.2. Mechanical Debridement
  • 9.2. Surgical
    • 9.2.1. Regenerative Procedures
    • 9.2.2. Resective Procedures

10. Peri-implantitis Market, by Implant Material

  • 10.1. Titanium
  • 10.2. Zirconia

11. Peri-implantitis Market, by Severity

  • 11.1. Mild
  • 11.2. Moderate
  • 11.3. Severe

12. Peri-implantitis Market, by End User

  • 12.1. Ambulatory Surgery Centers
  • 12.2. Dental Clinics
  • 12.3. Hospitals

13. Peri-implantitis Market, by Distribution Channel

  • 13.1. Direct Sales
  • 13.2. Distributors
  • 13.3. Online Channels

14. Peri-implantitis Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Peri-implantitis Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Peri-implantitis Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Peri-implantitis Market

18. China Peri-implantitis Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. BioHorizons IPH, Inc.
  • 19.6. CAMLOG Biotechnologies GmbH
  • 19.7. DENTSPLY SIRONA Inc.
  • 19.8. Geistlich Pharma AG
  • 19.9. Institut Straumann AG
  • 19.10. MIS Implants Technologies Ltd.
  • 19.11. Nobel Biocare Services AG
  • 19.12. Osstem Implant Co., Ltd.
  • 19.13. Osteogenics Biomedical, Inc.
  • 19.14. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PERI-IMPLANTITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PERI-IMPLANTITIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PERI-IMPLANTITIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES PERI-IMPLANTITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA PERI-IMPLANTITIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PERI-IMPLANTITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ADJUNCTIVE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ADJUNCTIVE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ADJUNCTIVE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LASER TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LASER TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LASER TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ALLOGRAFT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ALLOGRAFT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ALLOGRAFT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AUTOGRAFT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AUTOGRAFT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AUTOGRAFT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SYNTHETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY XENOGRAFT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY XENOGRAFT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY XENOGRAFT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON-RESORBABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON-RESORBABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON-RESORBABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESORBABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESORBABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESORBABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LOCAL ANTIBIOTIC THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LOCAL ANTIBIOTIC THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LOCAL ANTIBIOTIC THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MECHANICAL DEBRIDEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MECHANICAL DEBRIDEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MECHANICAL DEBRIDEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY REGENERATIVE PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY REGENERATIVE PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY REGENERATIVE PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESECTIVE PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESECTIVE PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESECTIVE PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY TITANIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY TITANIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY TITANIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ZIRCONIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ZIRCONIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ZIRCONIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MILD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MILD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MILD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DENTAL CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DENTAL CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DENTAL CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. GCC PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GCC PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. GCC PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 213. GCC PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. GCC PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. GCC PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 216. GCC PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 217. GCC PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 218. GCC PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 219. GCC PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 220. GCC PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. GCC PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. G7 PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. G7 PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. G7 PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 249. G7 PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. G7 PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. G7 PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 252. G7 PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 253. G7 PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 254. G7 PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 255. G7 PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 256. G7 PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. G7 PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. NATO PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. NATO PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. NATO PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 261. NATO PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. NATO PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. NATO PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 264. NATO PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 265. NATO PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 266. NATO PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 267. NATO PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 268. NATO PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. NATO PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES PERI-IMPLANTITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA PERI-IMPLANTITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)